SynthesisFrontiers in psychiatry2025
Comparative effectiveness of non-pharmacological interventions for anxiety, depression, and quality of life in individuals with autism spectrum disorder: A systematic review and network meta-analysis.
Synthesis in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Individuals with autism spectrum disorder (ASD) commonly experience comorbid depression, anxiety, and impaired quality of life (QoL), significantly affecting daily functioning and social adaptation. Non-pharmacological interventions (NPIs), offering an alternative without drug-related side effects, have gained increasing attention for emotional improvement and health promotion. However, the comparative effectiveness of different NPIs remains unclear, and clinical decisions lack robust evidence. Methods: This study adhered to the PRISMA-NMA guidelines. Five databases (PubMed, Embase, Cochrane Library, Web of Science, and EBSCOhost) were systematically searched to identify randomized controlled trials (RCTs) published before March 2025. A total of 67 RCTs involving 3,604 ASD participants were included. A frequentist network meta-analysis using a multivariate random-effects model was conducted in Stata, along with pairwise meta-analyses, to compare the relative effects of mindfulness-based interventions (MBI), cognitive behavioral therapy (CBT), behavioral and functional training (BEHAVE), physical activity (PHYS), sensory therapies (SENS), technology- and family-based interventions (TAFI), and other interventions (OTH) on anxiety, depression, and QoL. Standardized mean differences (SMDs) with 95% credible intervals (CIs) were used to estimate effects, and SUCRA rankings were calculated to assess comparative efficacy. Results: MBI showed the greatest improvement in anxiety symptoms (SMD = -0.84, 95% CI: -1.32 to -0.36; SUCRA = 91.4%), CBT ranked highest for depression reduction (SMD = -0.77, 95% CI: -1.25 to -0.28; SUCRA = 90.1%), and PHYS performed best for enhancing QoL (SMD = 0.59, 95% CI: 0.20 to 0.98; SUCRA = 87.5%). The analyzed population primarily consisted of high-functioning male individuals. Subgroup analyses showed stronger effects in adults and with moderate-duration interventions (9-16weeks). No significant inconsistency or publication bias was detected. Limitations: Findings mainly apply to high-functioning ASD populations without intellectual disability. Heterogeneity in interventions and assessments should be considered. Conclusions: Different NPIs exhibit distinct advantages in improving emotional symptoms and QoL among individuals with ASD. MBI, CBT, and PHYS demonstrate relative superiority for anxiety, depression, and QoL respectively, supporting their targeted application in clinical and rehabilitative settings. Future studies should prioritize long-term follow-up, refined intervention designs, and personalized strategies tailored to ASD subgroups to enhance clinical utility and scalability. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251021423.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.